These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 11286307)

  • 21. AMP-activated protein kinase control of energy metabolism in the ischemic heart.
    Lopaschuk GD
    Int J Obes (Lond); 2008 Sep; 32 Suppl 4():S29-35. PubMed ID: 18719595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-anginal effects of partial fatty acid oxidation inhibitors.
    Lam A; Lopaschuk GD
    Curr Opin Pharmacol; 2007 Apr; 7(2):179-85. PubMed ID: 17307396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trimetazidine in the myocardial cell mechanisms of cytoprotection.
    Labrid C
    Rom J Intern Med; 1998; 36(3-4):137-44. PubMed ID: 10822510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The malonyl CoA axis as a potential target for treating ischaemic heart disease.
    Ussher JR; Lopaschuk GD
    Cardiovasc Res; 2008 Jul; 79(2):259-68. PubMed ID: 18499682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative energy metabolism in cultured heart muscle and HeLa cells.
    Stanisz J; Wice BM; Kennell DE
    J Cell Physiol; 1983 Jun; 115(3):320-30. PubMed ID: 6853608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic therapy for patients with diabetes mellitus and coronary artery disease.
    Rosano GM; Vitale C; Fragasso G
    Am J Cardiol; 2006 Sep; 98(5A):14J-18J. PubMed ID: 16931201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carbohydrate-enriched diet impairs cardiac performance by decreasing the utilization of fatty acid and glucose.
    Pôrto LC; Savergnini SS; de Castro CH; Mario EG; Ferreira AV; Santos SH; Andrade SP; Santos RA; de Almeida AP; Botion LM
    Ther Adv Cardiovasc Dis; 2011 Feb; 5(1):11-22. PubMed ID: 21282201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Changes of myocardial enzymes related to glycolysis and fatty acid metabolism in chronic myocardial ischemia: experiment with pigs].
    Gong J; Wang HY; Pu JL; Zheng YL; Shen R; Yang MF; He ZX
    Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(31):2209-13. PubMed ID: 19080674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine.
    Stanley WC; Marzilli M
    Fundam Clin Pharmacol; 2003 Apr; 17(2):133-45. PubMed ID: 12667223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography.
    Mody FV; Singh BN; Mohiuddin IH; Coyle KB; Buxton DB; Hansen HW; Sumida R; Schelbert HR
    Am J Cardiol; 1998 Sep; 82(5A):42K-49K. PubMed ID: 9737485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fatty acid translocase/CD36 deficiency does not energetically or functionally compromise hearts before or after ischemia.
    Kuang M; Febbraio M; Wagg C; Lopaschuk GD; Dyck JR
    Circulation; 2004 Mar; 109(12):1550-7. PubMed ID: 15023869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy.
    Monti LD; Setola E; Fragasso G; Camisasca RP; Lucotti P; Galluccio E; Origgi A; Margonato A; Piatti P
    Am J Physiol Endocrinol Metab; 2006 Jan; 290(1):E54-E59. PubMed ID: 16174656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Myocardial metabolism abnormalities during ischemia and reperfusion].
    Argaud L; Ovize M
    Arch Mal Coeur Vaiss; 2000 Jan; 93(1):87-90. PubMed ID: 11227723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Metabolic therapy for heart failure].
    Loiacono F; Alberti L; Lauretta L; Puccetti P; Silipigni C; Margonato A; Fragasso G
    Recenti Prog Med; 2014; 105(7-8):288-94. PubMed ID: 25072544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Ischemic heart disease and left ventricular dysfunction: the role of trimetazidine].
    Belardinelli R
    Ital Heart J; 2004 Mar; 5 Suppl 2():23S-28S. PubMed ID: 15074774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiac metabolism in ischemic heart disease.
    Opie LH
    Arch Mal Coeur Vaiss; 1999 Dec; 92(12):1755-60. PubMed ID: 10665328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis.
    Folmes CD; Clanachan AS; Lopaschuk GD
    Curr Atheroscler Rep; 2005 Feb; 7(1):63-70. PubMed ID: 15683605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of free fatty acids metabolism as a therapeutic target in patients with heart failure.
    Fragasso G
    Int J Clin Pract; 2007 Apr; 61(4):603-10. PubMed ID: 17394434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting fatty acid and carbohydrate oxidation--a novel therapeutic intervention in the ischemic and failing heart.
    Jaswal JS; Keung W; Wang W; Ussher JR; Lopaschuk GD
    Biochim Biophys Acta; 2011 Jul; 1813(7):1333-50. PubMed ID: 21256164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel partial fatty acid oxidation inhibitor decreases myocardial oxygen consumption and improves cardiac efficiency in demand-induced ischemic heart.
    Wu L; Belardinelli L; Fraser H
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):372-9. PubMed ID: 18427280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.